1. INTRODUCTION
===============

*Staphylococcus aureus* is an important human pathogen that can cause a variety of diseases, including skin and soft tissue infections and systematic life threaten infections \[[@R1]\]. The continuing emergence of methicillin resistant *S. aureus* (MRSA), including hospital acquired (HA)-MRSA and community acquired (CA)-MRSA, is a major and increasing threat to public health. Most MRSA isolates are resistant to multiple antibiotics and consequently limit options of antibiotics for effective treatment of the MRSA infections \[[@R2]\].

It has been well established that overuse and misuse antibiotics are key factors that contribute to the spread of drug resistant bacterial pathogens \[[@R3]\]. In order to eliminate this factor, the rapid and correct diagnosis of the pathogen that results in infection is crucial for physicians to choose suitable antibiotics for the treatment bacterial infections. PCR-based approaches that have been successfully utilized for the rapid detection of *S. aureus*, including MRSA and MSSA, directly from various clinical specimens; thus we outline these PCR-based assays in this review.

2. IDENTIFICATION OF *STAPHYLOCOCCUS AUREUS* USING PCR
======================================================

2.1. Classic PCR Method to Detect *S. aureus*
---------------------------------------------

PCR approach has been routinely used to detect *S. aureus* from various samples. Based on a single-base-pair mismatch in the sequence of staphylococcal 16S ribosomal RNA gene, a PCR method was developed to identify *S. aureus*\[[@R4]\]. Moreover, a chromosomal 442bp DNA fragment specific to *S. aureus* was identified, and it was revealed that this specific 442bp fragment is ubiquitous in 195 clinical *S. aureus* isolates from patients in a variety of anatomical sites and geological locations in the world \[[@R5]\]. The conserved *S. aureus-*specific 442bp fragment DNA was sequenced and utilized for detection of *S. aureus* by colony PCR amplification *in vitro* using the primers, Sa442-1 (5'-AATCTTTGTCGGTACACGATATT CACG-3') and Sa442-2 (5'- CGTAATGAGATTTCAGT AGATAATACAACA-3') \[[@R5]\]. PCR buffer containing 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl~2~, 0.4 mM (each) the two *S. aureus*-specific primers, 200 mM (each) the dNPTs, and 0.5 U of *Taq*DNA polymerase (Promega, Madison, WI) \[[@R5]\]. A portion of colony was mixed in the PCR buffer, and PCR was done at following condition: 3 min at 96°C, 30 or 40 cycles of 1 s at 95°C for the denaturation, and 30 s at 55°C for the annealing-extension \[[@R5]\].This PCR assay is simple and rapid; it can be done within 1 h \[[@R5]\]. This provides a novel diagnostic tool for the diagnosis of *S. aureus*infections. Different target genes for diagnosis PCR may affect the specificity and sensitivity. Using *nuc* gene (encoding nuclease) as a target for PCR, it was shown 100% positive rate with as less as 0.69 pg of chromosomal DNA or 10 CFU bacterial cells \[[@R6]\]. Briefly, the bacterial cells wre harvested by centrifugation, lysed in lysis buffer (20 mM Tris-HCl \[pH 8.3\], 50 mM KCl, 1.5 mM MgCl~2~, 0.50% Tween 20, 0.45% Nonidet P-40, 0.01% gelatin, and 60 p.g of proteinase K per ml) at 55°C for 1 h, then followed by PCR amplification as described \[[@R6]\]. From culture positive blood samples, the *nuc* nested PCR was able to detect 50 copies or 50 CFU/ml of blood sample, whereas 10 CFU/ml of blood sample were enough for detection of *S. aureus* by using the *sodA*nested PCR assays \[[@R7]\]. The *S. aureus* genomic DNA was purified using a bacterial genomic DNA kit (Sigma-Aldrich, St. Louis, MO) and utilized as a template DNA for PCR amplification of the *nuc* and *sodA* as described \[[@R7]\]. It was demonstrated that the *sodA* nested PCR approach is highly specific (specificity 100%, 95% CI 0.92-1) and sensitive (sensitivity 89%, 95% CI 0.75-0.96), and can be utilized to determine whether sepsis is caused by *S. aureus* in two hours using 1 ml of blood sample without the need of culture \[[@R7]\]. Moreover, a *S. aureus* specific 289-bp of *vicK* gene was revealed and could be utilized to differentiate *S. aureus* from other *staphylococcus* species by PCR as described \[[@R8]\].

2.2. PCR Identification of Methicillin-resistant *S. aureus* (MRSA)
-------------------------------------------------------------------

Due to the emergence of MRSA, a series of PCR approaches have been developed for identification of MRSA (Table **[1](#T1){ref-type="table"}**). It is well established that the *femA* gene exists in *S. aureus*, including MRSA and MSSA, but is absent in coagulase-negative *staphylococcus* (CNS) strains. On the other hand the *mecA* gene (encoding high-level methicillin resistance) is present in both MRSA and methicillin-resistant CNS. Therefore, both the *femA* and *mecA* genes have been successfully used for detection of MRSA \[[@R9]\]. PCR of both *mecA* and *nuc* genes from specimens was used for diagnosis of MRSA infections with 97% specificity and 100% sensitive and shortened the turnaround time to 48 hours \[[@R10]\]. This method is routinely utilized in clinical laboratories for detecting MRSA in surveillance samples \[[@R10]\]. The colonies were picked and suspended in 0.5 N NaCl and used as template DNA for PCR using the *mecA* and *nuc* specific primers as described \[[@R10]\]. A PCR-based dipstick assay was developed for direct detection of MRSA from clinical swab specimens. The sensitivity and specificity of this approach reached 94.1% and 98.3%, respectively, with a lower cost \[[@R11]\]. Moreover, based on the sequence linking the right junction of the SCCmec elements and the adjacent chromosomal region, a PCR method was developed to detect MRSA with 100% specificity using a forward primer specific targeting the SCCmec element and a reverse primer specific targeting the *orfX* region \[[@R12]\]. The genomic DNA was purified from the lysostaphin treated staphylococcal cells, and 10 ng of gDNA was used as a template for PCR in 25μl PCR mixture (2.5 pmol of each primer and 200 μM each dNTP, 10 mM Tris-HCl, pH 9.0, 1.5 mM MgCl~2~, 500 mM KCl and 1.3 U of rTaq DNA polymerase) in a thermocyclyer as described \[[@R12]\]. The recent emergence of community-acquired (CA)-MRSA has caused a serious public concern. It is important to develop a robust tool to detect CA-MRSA. It has been found that the *pbp3* gene is specifically present in the CA-MRSA isolates. A single allele-specific PCR targeting the G88A polymorphism has been developed using purified genomic DNA as a template and CaMRSA-For-AA or CaMRSA-For-AG and CaMRSA-Rev-4 primers \[[@R13]\]. This approach could effectively be utilized to detect USA300-MRSA with 100% sensitive and specificity as well as CA-MRSA with 91.5% sensitive and 100% specificity \[[@R13]\]. MRSA complex clone, CC398, is an important zoonotic agent due to its prevalence in livestock. Based on the Sau1-HsdS1 lineage-specific type I restriction-modification system, a PCR method has been developed to detect MRSA CC398 in both hospitals and on farms \[[@R14]\]. Recently, a dry reagent-based thermostabilized PCR has been established for the detection of MRSA through simultaneous amplification of 16s rRNA, *femA*, *mecA* and *lukS* genes with 100% sensitivity and specificity \[[@R15]\]. The bacterial cells was lysed by boiling and used as a template for PCR amplification using thermostabilized PCR reagents \[[@R15]\]. Moreover, it was determined that the limitation of detection is 10^6^ CFU and 10 ng of genomic DNA using this approach, which is similar to conventional PCR \[[@R15]\].

3. DETECTION OF MRSA USING MULTIPLEX PCR
========================================

3.1. Multiplex PCR for Identification of MRSA
---------------------------------------------

To enhance the specificity and efficiency of detecting MRSA, a variety of multiplex PCR has been developed based on different *S. aureus* specific target genes (Table **[2](#T2){ref-type="table"}**). Two pairs of primers specific to staphylococcal *nuc* and *mecA*, respectively, were designed and utilized for multiplex PCR using purified genomic DNA as a template for PCR amplification of a 280bp *nuc* based fragment and a 533bp *mecA* based fragment \[[@R16]\]. It was revealed that the multiplex amplification of *nuc* is100% specific compared with the detection of coagulase production; moreover, more that 96.8% to 97.7% specificity could be achieved for detecting MRSA by multiplex amplifying *mecA* compared with *in vitro*oxacillin susceptibility assays \[[@R17]\]. The multiplex amplification of *femA* or *femB* (fragment specific for *S. aureus*) and *mecA* fragments has been successfully used for the identification of MRSA isolates from patient samples \[[@R18]-[@R20]\]. The specimens were homogenized in TE buffer (20 mM Tris HCl \[pH8.0\], 10 mM EDTA) with 2% SDS; the bacterial cells were harvested from homogenate by centrifugation, lysed with TE buffer containing 1% Triton X-100 and 50µg lysostaphin. The lysis was further treated with proteinase K and followed by bacterial DNA purification, which was subjected to multiplex PCR \[[@R18]\]. Recently, a multiplex PCR approach was developed for the differentiation of MRSA and methicillin- resistant coagulase negative *Staphylococcus* (MR-CNS) isolates from burn patients by colony PCR amplification of 16S rRNA, *mecA*, and *nuc* gene fragments \[[@R21]\]. A *mecA* homologue, *mecC*, has been identified and possesses 70% identity with *mecA*at the DNA level \[[@R22]\], and a *mecC*-based multiplex PCR was utilized for the identification of MRSA and the detection of *mecA* and *mecC* genes using extracted DNA as a template \[[@R23]\].

3.2. Multiplex PCR for Characterization of MRSA
-----------------------------------------------

The multiplex colony PCR amplification of the 310, 456, and 651-bp fragments of *mecA*, *ileS*-*2,*(encoding high-level mupirocin resistance), and *femB*, respectively, was able to identify multidrug resistant MRSA from a single colony \[[@R24]\]. In order to discriminate MRSA, MR-CoNS, and mupirocin-resistant staphylococci, a quadriplex PCR was established with 100% sensitivity, specificity, and accuracy by targeting 16S rRNA (*staphylococcus* genus specific), *nuc* (*S. aureus* specific), *mecA* and *mupA* (mupirocin resistant gene) gene fragments \[[@R25]\]. The genomic DNA was extracted from bacterial colonies and used as a template for amplification following the PCR condition as described \[[@R25]\]. A multiplex PCR approach targeting of *mecA* and *pvl* (encoding Panton-Valentine Leukocidin) allows us to identify both USA300 and USA400 CA-MRSA isolates \[[@R26]\]. Thus, the quadriplex PCR of *S. aureus* 16S rRNA, *nuc*, *mecA* and *mupA* genes enables us to simultaneously identify a mupirocin resistant MRSA, while the multiplex PCR of *mecA* and *pvl* genes allows us to distinguish prevalent USA300 and USA400 CA-MRSA. Based on a unique more than 6 AT repeats signature and *pvl* gene in USA300 chromosomal DNA, a multiplex PCR assay was developed using genomic DNA as a template for PCR amplification that can be utilized to directly identify USA300 MRSA strains \[[@R27]\]. Moreover, using bacterial lysates as template and optimized concentration of primer for each gene and PCR condition, a pentaplex PCR was developed for rapid identification and characterization of MRSA isolates by simultaneous PCR amplification of 16S rRNA gene, *femA*, *mecA*, *lukS* (encoding Panton-Valentine leukocidin, PVL), and an internal control gene fragments \[[@R28]\]. Using a similar strategy, a multiplex PCR for 16S rRNA, *nuc*, *mecA*, *pvl*, *czrC* (cadmium/zinc) and *qacA/B* (encoding antiseptic resistance) gene fragments was utilized to identify and characterize MRSA, PVL-positive and negative *S. aureus*, as well as discriminate CNS from the ocular samples \[[@R29]\]. The above studies demonstrated that the multiplex PCR provides a rapid and reliable approach to identify and characterize MRSA isolates. The sensitivity, specificity, and efficiency of different multiplex PCR assays for identification and characterization of MRSA were compared and outlined in Table **[2](#T2){ref-type="table"}**.

4. IDENTIFICATION OF *S. Aureus*, INCLUDING MRSA, USING REAL-TIME PCR
=====================================================================

Different real-time PCR assays have been established to the identification of *S. aureus* (Table **[3](#T3){ref-type="table"}**). *fnbA*gene (encoding a fibronectin-binding protein A) was utilized for real-time PCR (RT-PCR) to quantitatively detect *S. aureus* directly from lower respiratory tract samples of the patients \[[@R30]\]. The genomic DNA was purified from bacterial samples and used as a template DNA for real-time PCR as described \[[@R30]\]. However, it is possible to obtain false negative results*,*as not every *S. aureus* isolate possesses *fnbA* gene \[[@R31]\]. Based on the fact that the *mecA*gene is located in the staphylococcal cassette chromosome *mec*, a MRSA-specific single-locus real-time PCR was developed for rapid detection of MRSA directly from swab samples \[[@R32]-[@R36]\]. The swab was votexed in 1 ml sample buffer, which was followed by centrifugation. The pellet was lysed in the lysis buffer and used for real-time PCR as described \[<http://www.geneohm.com>, [@R32]\]. Using this approach more than 92% sensitivity and 99% specificity could be achieved; however, it should be point out that other methods may be needed to confirm the assays, because using IDI-MRSA method 4.7% swab samples did not yield PCR product and 5.1% swab samples generated false positive \[[@R32]\]. RT-PCR has been successfully used to detect MRSA directly from blood culture bottles through targeting both *mecA* and *orfX* genes within 2 h \[[@R37]\]. The bacterial lysis from 1μl of blood culture was used as a template for RT-PCR testing using the Cepheid SmartCycler^®^ system (Cepheid, Sunnyvale, CA) with GeneOhm reagents (GeneOhm Sciences, San Diego, CA). This approach could reach 97% accuracy for the detection of MRSA directly from the cultured blood samples \[[@R37]-[@R39]\]. IDI-MRSA is a RT-PCR based and qualitatively diagnostic approach for the rapid detection of MRSA directly from nasal swabs (Infectio Diagnostic, Inc., Sainte-Foy, Québec, Canada). This approach could achieve 91.7% sensitivity and 93.5% specificity for the diagnosis of MRSA directly from nasal swab specimens \[[@R40]\]. The IDI-MRSA assay can also be used to detect MRSA from pooled and individual samples cultivated in a selective broth medium with 96% sensitivity and specificity compared to the bacterial culture \[[@R41]\]. Different approaches of genomic DNA extraction from blood culture were compared for RT-PCR detecting MRSA, and the results showed that the benzyl alcohol extraction is more reliable for the real-time amplification of the *mecA* and *nuc* genes and the rapid detection of MRSA /MSSA from the positive blood culture samples \[[@R42]\].

5. IDENTIFICATION OF *S. Aureus*, INCLUDING MRSA USING MULTIPLEX RT-PCR APPROACHES
==================================================================================

Different multiplex real-time PCR methods have been developed for diagnosis of MRSA from clinical specimens (Table **[4](#T4){ref-type="table"}**). By targeting *mecA*, *ermA*, and *femA* genes, a triplex RT-PCR was developed using TaqMan probes and optimized concentrations of primers for the identification of MRSA from collected *S. aureus*samples within 3 h \[[@R43]\]. Based on the staphylococcal cassette chromosome *mec* (SCCmec) and *S. aureus* specific *orfX* gene sequences, a set of primers specific to SCCmec sequence and three *orfX* specific beacon probes were designed and successfully used for rapid multiplex RT-PCR for the identification of MRSA from clinical samples \[[@R44]\]. Either purified genomic DNA or crude DNA extract from bacterial cells could be utilized as a template for amplification. The sensitivity of this approach is high, and it could detect MRSA from a sample with 25 CFU of bacteria. Moreover, it provides a powerful approach to differentiate MRSA from clinical samples with different staphylococci \[[@R44],[@R45]\]. The specificity could be improved to reduce false positive results by including 16S rRNA gene in the multiplex RT-PCR \[[@R46]\]. Moreover, The specificity of the diagnosis multiplex RT-PCR assay could also be enhanced by simultaneously detecting two *S. aureus* specific DNA sequences including Sa442 DNA sequence and *coa*gene \[[@R47]\]. Simultaneous amplification of *mecA*, *lukF* and *lukS* genes using RT-PCR was also used to detect MRSA from clinical swab samples with 95% sensitivity and 99% specificity \[[@R48]\]. It was revealed that two of the PVL-positive swabs were MRSA and three were MSSA \[[@R48]\]. Moreover, the multiplex RT-PCR amplification of *nuc*, *mecA*, *tst* and *lukS-PV* genes enables to identify MRSA isolates carrying toxic shock syndrome toxin I and/or Panton-Valentine leukocidin gene using the genomic DNA prepared from the clinical samples \[[@R49]\]. It could be utilized to detect MRSA directly from nasal samples based upon the ability of SYBR Green I integrating into six dual priming AT-rich primers as described \[[@R50]\]. This approach could detect 1 pg genomic DNA of MRSA isolates with relatively high sensitivity (93.5%) and specificity (82.9%) for the identification of MRSA from nasal samples \[[@R51]\]. The *tuf* gene encodes an essential elongation factor Tu that is specific to *Staphylococcus* genus; the*nuc* gene is *S. aureus*specific; the *atlE* gene (encoding autolysin E) is *S. epidermidis* specific, the *gap* gene (encoding glyceraldehyde-3-phosphate dehydrogenase) is *S. hominis*specific, *mvaA* gene (encoding HMG-CoA reductase) is *S. heamolyticus* specific; and the *mecA* gene encodes methicillin resistance. Thus, the RT-PCR of these genes not only can be utilized to differentiate these species of staphylococci, including coagulase-positive *S. aureus* and coagulase-negative staphylococci, but also can be used to identify methicillin resistant staphylococci, including MSSA and MRCNS. By targeting the *tuf*, *nuc* and *mecA* genes, a triplex RT-PCR was developed to identify MRSA directly from positive blood culture bottles with more than 99% sensitivity and specificity \[[@R51]\]. Furthermore, a double triplex RT-PCR was established to detect *tuf*, *nuc* and *mecA* genes in one reaction and *atlE*, *gap and mvaA* genes in another reaction tube simultaneously \[[@R52]\]. This multiplex RT-PCR strategy has been successfully used to detect and differentiate *S. aureus*, *S. epidermidis*, *S. hominis*, and *S. heamolyticus* directly from Gram-positive blood culture bottles \[[@R52]\].

6. IDENTIFICATION OF MRSA USING DIFFERENT AUTOMATED MRSA RT-PCR SYSTEMS
=======================================================================

Due to the demand of rapid diagnosis of MRSA infections in public health sector, various automatic MRSA detection systems have been developed and utilized for high throughput screening of MRSA isolates directly from clinical samples (Table **[5](#T5){ref-type="table"}**). A GeneXpert Dx system has been used for the identification of MRSA using an Xpert MRSA cartridge holding necessary reagents for RT-PCR detection of SCCmec. This system was used to detect MRSA-specific DNA sequence directly from different clinical samples, including transtracheal aspirates and bronchoalveolar fluid, blood cultures, and swabs \[[@R53]-[@R58]\]. Different sensitivity and specificity have been determined for the detection of MRSA from different clinical samples. For blood culture samples an Xpert MRSA/SA Blood culture assay could achieve a higher specificity (100%), but low sensitivity (75%) for the detection of MRSA \[[@R54]\]; for nasal swabs the sensitivity and specificity of MRSA detection were 69.2% and 97.7%, respectively \[[@R55],[@R59]\]. No significant difference of performance exhibited between the Xpert MRSA and BD GeneOhm MRSA assays compared to golden standard culture methods \[[@R60]-[@R62]\]. A GenomEra CDX PCR system was developed for the rapid detection of MRSA from positive blood cultures with higher sensitivity (100%) and specificity (99.8%) \[[@R63]\]. Roche Diagnostics has developed a LightCycler MRSA Advanced Test system for RT-PCR detection of MRSA directly from nasal swabs with overall 83.3% sensitivity and 99% specificity \[[@R64]\]. It was found that the sensitivity and specificity are similar between the LightCycler MRSA Advanced Teat and the Xpert MRSA assay for detection of MRSA from human swab specimens \[[@R65]\].

7. IDENTIFICATION OF *S. AUREUS* AND MRSA USING ISOTHERMAL AMPLIFICATION APPROACHES
===================================================================================

Although PCR has been successfully used to amplify a specific DNA fragment, it requires a thermocycler and involves many cycles of reactions, including DNA denature, primer annealing, and extension, by changing temperature at different stages of reaction. Recently, the isothermal application technologies have been developed for amplification of DNA fragments; it costs effectively and can be used to rapidly amplify a specific DNA sequence, as it doesn't requires any thermocyclers to change reaction temperature. A helicase-dependent isothermal amplification (HDA) is based on the double-strand DNA unwinding activity of a helicase to separate strands, allowing primer annealing and extension with DNA polymerase \[[@R66]\]. This approach was employed to detect *S. aureus* and MRSA directly from gram-positive blood culture medium by targeting the *nuc* and *mecA* genes using a disposable device. Both the sensitivity and specificity could reach to 100% for clinical diagnosis of *S. aureus* and 100% and 98% for MRSA detection; the detection limitation was 50 CFU/reaction \[[@R67]\]. From the clinical swab samples, the overall relative sensitivity and specificity were 89% and 94%, respectively, for detection of *S. aureus* using the HDA-based assay \[[@R68]\]. A loop-mediated isothermal amplification (LAMP) uses 4-6 primers that recognizing 6-8 different regions of target DNA. A strand-displacing DNA polymerase with two primers initiates DNA synthesis and forms two loop structures to facilitate subsequent amplification of target DNA \[[@R69]\]. A LAMP-based approach was employed to rapidly and directly detect MRSA in blood cultures by isothermal amplification of *spa* and *mecA*genes at 63°C. The diagnostic values of LAMP could reach to 92.3% sensitivity, 100% specificity, 100% positive predictive value, and 96.9% negative predictive value \[[@R70]\]. The results of LAMP were consistent with those of a duplex RT-PCR assay, but the LAMP-based detection is cost-effective \[[@R70],[@R71]\]. The LAMP-based technology has been explored to detect and differentiate *S. aureus*, including MRSA/MSSA, and to determine antibiotic resistant profiles of *S. aureus* from different samples by targeting *spa*/*mecA*, *nuc*/*mecA*, *orfX*, *femA*, f*emB*/*mecA*/*qacA*/*B* \[[@R70]-[@R74]\].

The comparison of sensitivity and specificity among various isothermal amplification methods for detection of *S. aureus* and/or MRSA is listed in Table **[6](#T6){ref-type="table"}**.

CONCLUSION
==========

Although different PCR-based molecular diagnostic technologies, including end-point PCR, real-time PCR, multiplex PCR, and isothermal amplification of specific target DNA sequence, have been successfully established and utilized for rapid detection of *S. aureus*, including MRSA and MSSA, directly from various clinical specimens, alternative approaches such as traditional golden standard culture method are necessary to further confirm the results due to false positive and false negative results. Targeting different genes and different PCR approaches can give distinct sensitivity and specificity. Thus, it is important to design reasonable strategy for rapid screening of MRSA directly from clinical samples. The recently developed isothermal amplification techniques provide a more convenient and cost-effective strategy for the rapid identification of *S. aureus*.
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###### 

PCR identification of methicillin-resistant *S. aureus* (MRSA).

  Method                                                      Gene                                                  Specimen                  Sensitivity   Specificity   Time               Reference
  ----------------------------------------------------------- ----------------------------------------------------- ------------------------- ------------- ------------- ------------------ --------------------
  PCR                                                         *mecA* and *nuc* sau1-hsdS1                           clinical swabs isolates   100%          97%-100%      48 h               \[[@R10], [@R14]\]
  Thermo stabilized PCR                                       *mecA*, *femA*,*16S rRNA*, *lukS*                     Nasal swabs               100%          100%          same-day results   \[[@R15]\]
  GenomEra™ MRSA/SA                                           *mecA*; conserved genomic *S. aureus* sequence (SA)   blood culture             100 %         99.8 %        within 1 h         \[[@R63]\]
  gold nanoparticles (Au NPs) for direct colouri metric PCR   *23S rRNA* and *mecA*                                 clinical specimens        97.14%        91.89%        NA                 \[[@R75]\]
  Isothermal signal-mediated amplification of RNA(CytAMP)     *coa* and *mecA*                                      clinical isolates         100%          100%          3.5 h              \[[@R22]\]

###### 

Multiplex PCR for the identification and characterization of MRSA.

  Method                      Gene                                                                                                 Specimen                 Sensitivity   Specificity   Time          Reference
  --------------------------- ---------------------------------------------------------------------------------------------------- ------------------------ ------------- ------------- ------------- --------------------------------------------
  multiplex PCR-immunoassay   *mecA* and *femB*                                                                                    screening swabs          NA            NA            24 h          \[[@R76]\]
  Multiplex PCR               280-bp *nuc-*based fragment,533-bp *mecA-*based fragment, *mecA*, *mecC*, *femB*,*16S rRNA*, *nuc*   isolates                 100%          98%-100%      3h, 5h        \[[@R16], [@R23], [@R19], [@R21], [@R77]\]
  Quadriplex PCR              *16S rRNA*, *nuc*, mecA and mupA                                                                     isolates                 100%          100%          NA            \[[@R25]\]
  multiplex PCR               *femA* and *mecA*                                                                                    endotracheal aspirates   NA            NA            \> 6 h        \[[@R18]\]
  multiplex PCR               *S. aureus* species-specific and *mecA* gene segments                                                Nasal swabs              96.5%         100%          within 24 h   \[[@R78]\]
  triplex qPCR                *mecA, femA*                                                                                         clinical swabs           100%          64%           \> 6 h        \[[@R20]\]

###### 

Identification of *S. aureus*, including MRSA, using Real-Time PCR.

  Method                                           Gene                 Genus         Specimen                            Sensitivity   Specificity   Time              Reference
  ------------------------------------------------ -------------------- ------------- ----------------------------------- ------------- ------------- ----------------- --------------------
  single-locus real time PCR                       *mecA*               MRSA          nasal swab                          92.3%         98.6%         \<90 min          \[[@R32]\]
  Taq Man real time PCR                            *fnbA*               S. aureus     lower respiratory tract specimens   100%          100%          2h                \[[@R30]\]
  Real time PCR(Roche analyte-specific reagents)   *mecA*               *S. aureus*   nasal swabs                         NA            NA            within 3-5 h      \[[@R33]\]
  In house real-time PCR                           *mecA*               *S. aureus*   nasal swabs                         NA            NA            within 3 to 5 h    
  Real time PCR                                    *mecA*, *orfX,nuc*   MRSA          blood cultures                      100%          99.2%         2h, 3 h           \[[@R37], [@R42]\]
  Real time PCR                                    *SCC*mec**, *orfX*   MRSA          nasal swabs                         100%          98.4%, 99%    \<1h              \[[@R34], [@R79]\]
  Real time PCR                                    *Nuc,* *orfX*        MRSA          clinical swabs                      93%,93.3%     89.6%, 100%   \< 90 min         \[[@R35], [@R80]\]
  Real time PCR                                    *SCCmec*             MRSA          screening swabs                     98.6 %        99.4 %        \<7h              \[[@R36]\]
  Real time PCR                                    *orfX*               MRSA          clinical isolates                   98%           100%          \< 90 min         \[[@R35]\]

###### 

Identification of *S. aureus*, including MRSA, using multiplex RT-PCR.

  Method                         Gene                                               Genus                                   Specimen             Sensitivity    Specificity    Time     Reference
  ------------------------------ -------------------------------------------------- --------------------------------------- -------------------- -------------- -------------- -------- --------------------
  Multiplex real time PCR        *SCCmec*/*orfX* junction; *lukF* and *lukS*        MRSA                                    nasal swabs          95%, 93.5%     99%, 82.9%     NA       \[[@R48], [@R50]\]
  Multiplex real time PCR        various SRE sequences, *orfX*(Xsau325), *SCCmec*   MRSA                                    clinical specimens   NA             NA             \<1 h    \[[@R44], [@R45]\]
  Triplex real time PCR          *mecA,* *coa,* Sa442 *,* *ermA,femA*               *S. aureus and*methicillin resistance   Clinical isolates    100%           100%           3h       \[[@R43], [@R47]\]
  Triplex real time PCR          *tuf*, *nuc*, and *mecA*                           *S.aureus*                              blood culture        99.2%-100.0%   98.7%-100.0%   90 min   \[[@R51]\]
  Double triplex real time PCR   *tuf*, *nuc*, *mecA*, *atlE*, *gap* and *mvaA*     *S.aureus*                              blood culture        NA             NA             83 min   \[[@R52]\]

###### 

Identification of MRSA using different automated MRSA RT-PCR systems.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Method                                                   Gene                                                    Genus   Specimen                             Sensitivity                                         Specificity                                          Time                                                                     Reference
  -------------------------------------------------------- ------------------------------------------------------- ------- ------------------------------------ --------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------
  ChromID MRSA                                             *mecA*                                                  MRSA    Nasal swabs                          100%                                                87.0%                                                NA                                                                       \[[@R84]\]

  BD GeneOhm\                                              Junction of *SCCmec* and *orfX*                         MRSA    swabs                                95.7%, 78.7%, 84.3%, 93.3%, 92%, 91.7%, 96%, 100%   91.7%, 96.9%, 99.2% ,95.2%, 98%, 93.5%, 96%, 98.6%   5-6min per sample, or 1.5 h                                              \[[@R40], [@R41], [@R61], [@R62], [@R81], [@R82], [@R87], [@R90]\]
  (IDI-MRSA)                                                                                                                                                                                                                                                                                                                                      

  real-time PCR analyte-specific reagent (ASR) assay                                                               MRSA    nasal swabs                          100%                                                92%                                                  \< 2 hours                                                               \[[@R85]\]

  the GenomEra™ MRSA/SA                                    *mecA* and conserved genomic *S. aureus*sequence (SA)   MRSA    blood culture                        100.0%,                                             99.8 %                                               within 1 h                                                               \[[@R63]\]

  Xpert MRSA                                               *SCCmec,spa*, *mecA*                                    MRSA    swabs                                99%, 100%, 95%, 78.3%, 90%, 89.3% 94.3% 86.3%       95.5%, 90.7%, 97%, 97.7%, 97%, 97.9% 93.2% 94.9%     \<1 h; 1.9 h-2.6 h; or 2.35min per sample, PCR cycling time of ≤72 min   \[[@R53], [@R55], [@R56], [@R59], [@R60], [@R65], [@R86]\]

  Xpert MRSA                                               *SCCmec*                                                MRSA    BC specimens                         75%                                                 100%                                                 1.5 h                                                                    \[[@R54]\]

  Xpert MRSA                                               *spa*, *mecA*, *SCCmec*                                 MRSA,   lower respiratory tract secretions   99.0%                                               72.2%                                                \<1 h                                                                    \[[@R58]\]

  Xpert MRSA                                               *spa*, *mecA*, junction of *SCCmec* and *orfX*          MRSA    Bone and joint infection             94.4%                                               100%                                                 \< 1 h                                                                   \[[@R57]\]

  LightCycler Test                                         *SCCmec*/*orfX*, *mecA,*\                               MRSA    swabs                                95.7%, 88%, 83.3%, 95.2%, 100%, 95.2%               90.8%, 95.9%, 99.0%, 95.5%, 90.1%, 96.4%             1.40/4.74min per sample                                                  \[[@R64], [@R65], [@R85], [@R89], [@R90]\]
                                                           *SCCmec*integration site                                                                                                                                                                                                                                                               

  LightCycler Test                                         fragment of *mecA* and fragment of *Sa442*              MRSA    clinical isolates                    NA                                                  NA                                                   within 4 h                                                               \[[@R83]\]

  LightCycler Test                                         *mecA*                                                  MRSA    blood culture                        100%                                                100%                                                 NA                                                                       \[[@R88]\]

  duplex LightCycler PCR                                   *mecA, sa442*                                           MRSA    clinical isolates and type strains   100%                                                100%                                                 70 min                                                                   \[[@R91]\]

  real-time fluorescence PCR with the LightCycler device   *sa442* and a 98-bp fragment                            MRSA    blood cultures                       100%                                                100%                                                 2 h                                                                      \[[@R39]\]

  IsoAmp RapidStaph Detection kit                          *nuc*, *mecA*                                           MRSA    blood culture                        100%                                                100%                                                 \<1.5 h                                                                  \[[@R67]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Identification of *S. aureus*, including MRSA, using isothermal amplification.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Method                                                    Gene                    Genus          Specimen               Sensitivity   Specificity   Time     Reference
  --------------------------------------------------------- ----------------------- -------------- ---------------------- ------------- ------------- -------- --------------------
  Loop-mediated isothermal amplification                    *spa*, *mecA*           MRSA           Blood cultures         92.3%         100%          2 h      \[[@R70]\]

  Loop-mediated isothermal amplification                    *nuc*, *mecA*, *orfX*   *S. aureus*\   Strains and isolates   98.4%         100%          60 min   \[[@R71], [@R72]\]
                                                                                    MRSA                                                                       

  Loop-mediated isothermal amplification                    *femA*, *arcC*          MRSA,\         Clinical samples       96.9%, 100%   100%          80 min   \[[@R73], [@R92]\]
                                                                                    *S. aureus*                                                                

  Isothermal signal-mediated amplification of RNA(CytAMP)   *coa*and *mecA*         MRSA           Clinical isolates      100%          100%          3.5 h    \[[@R93]\]

  3 Loop-mediated isothermal amplification                  *femB*, *mecA*          MRSA           Isolates               NA            100%          NA       \[[@R74]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
